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Introduction
Bone mass and bone turnover in adults is maintained locally by the balance between osteoclastic bone resorption and osteoblastic bone formation, and multiple coupling 'factors' maintain this servo system at its physiological (homeostatic) steady state (Harada and Rodan, 2003) . High bone turnover initiated during menopause and the succeeding progressive reduction in bone mass and microarchitecture result in an increase in the fragility of bone and its susceptibility to fractures, all characteristics of osteoporosis (Rodan & Martin, 2000) .
The intermittent application of human parathyroid hormone fragment (hPTH 1-34) as a first bone-anabolic treatment has illustrated novel cues for effectively restoring lost bone mass, structure and strength in the clinic (Dobnig, 2004) , however, primarily for severely osteoporotic patients.
Recent genetic evidence has substantiated a central role for the Wnt-signaling components low-density lipoprotein receptor-related proteins (LRP4, LRP5 and LRP6) in bone mass accrual during development (Gong et al., 2001; Kokubu et al., 2004; Mani et al., 2007; . The keystone description of high bone mass (HBM) phenotypes in human triggered by single amino-acid substitutions in LRP5 (Boyden et al., 2002; Little et al., 2002; van Wesenbeeck et al., 2003) have heightened interest in the Wnt/LRP pathway in bone homeostasis extending into adulthood (Baron and Rawadi, 2007 ). An increasing number of negative regulatory mechanisms intersecting at Wnt-LRP5/6 have been identified in bone, among those most relevant are endogenous inhibitors of the Wnt-signaling pathway including the DKK proteins (Krupnik et al., 1999) , Kremen-proteins and Sclerostin (Semenov et al., 2005; Ellies et al., 2006) .. DKK1 binds with high affinity to LRP4/5/6 receptors and Kremen proteins Mao et al., 2002; Bafico et al., 2001; Mao et al., 2001; Fleury et al.; . Interestingly, LRP5 HBM is refractory to the inhibitory activities of DKK1 (Boyden et al., 2002; Ai et al., 2005) suggesting that this pathway promises enormous opportunities to identify novel treatment paradigms and to intervene pharmacologically with the course of low bone mass diseases (Khoshla et al., 2008) . Although DKK1 is expressed and secreted within the bone This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on jpet.aspetjournals.org Downloaded from JPET #181404 5 microenvironment (Robling et al., 2008) , the protein is soluble and detectable in the peripheral circulation (Kaiser et al., 2008) . These cues have led us to develop monoclonal antibodies as reagents that interfere functionally with the DKK1 role in Wnt-signaling and bone formation.
Recently DKK1 antibodies have been introduced into mice and have demonstrated efficacy in disease models of rheumatoid arthritis (Diarra et al., 2007) and multiple myeloma (Yaccoby et al., 2007; Fulcinitti et al., 2009; Heath et al., 2009) where DKK1 levels are elevated. These findings corroborate a critical role for DKK1 in the bone microenvironment and point to the potential clinical applicability of DKK1 neutralizing agents Gavriatopoulou et al., 2009 ), However, proof of principle in crucial animal models with systemic osteopenia through estrogen-deficiency emulating post-menopausal osteoporosis in humans has not been demonstrated.
Here we describe a pharmacologic approach applying a novel fully human monoclonal anti-DKK1 antibody (Glantschnig et al., 2010) . Our data support the hypothesis that systemic restoration of bone mass can be achieved via pharmacologic modulation of DKK1 bioavailability with concomitant resolution of osteopenia in murine animal models. More importantly, we provide evidence for the inhibitory activity and the rate limiting role of DKK1 on bone mass accrual in the aged ovariectomized primate. Thus we provide a first description of an experimental therapeutic and putative clinically relevant treatment modality specifically targeting DKK1 for the treatment of low systemic bone mass, a characteristic of post-menopausal osteoporosis.
This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods
Rhesus DKK1 protein. Rhesus DKK1 fusion protein was expressed and purified as described previously (Glantschnig et al., 2010) and used in all biological assay.
Generation of anti-DKK1 antibody RH2-18. Cambridge Antibody Technology (Cambridgeshire, UK) phage displayed single chain Fv (scFv) antibody libraries were panned alternately against biotinylated rhesus or mouse DKK1 (R&D Systems, Minneapolis, MN) as described (Glantschnig et al., 2010) . The scFv heavy chain variable regions were fused inframe with the IgG2m4 constant region ) and resulting anti-DKK1 antibody structures were published previously (Glantschnig et al., 2010) . Anti-DKK1 antibody was expressed in Chinese hamster ovary (CHO) cells using a mammalian expression vector and the secreted antibodies were purified from medium using standard protein A/G based affinity chromatography following manufacturers instruction (Pierce, Rockford, IL). Anti-DKK1 antibody RH2-18 binds to human DKK1 with high affinity, its binding epitope is located within the C-terminal domain of DKK1 and does not show detectable binding to DKK2 or DKK4 proteins (Glantschnig et al., 2010) . This experimental antibody was used in all procedures below.
Pharmacokinetic studies. All animal procedures were performed according to approved protocols and in accordance with the recommendations for the proper care and use of laboratory animals. These studies were carried out under the Institutional Animal Care and Use Committee (IACUC) of Merck Research Laboratories (West Point, PA). Female C57/BL6NTac mice (Taconic, Hudson, NY) were ovariectomized and housed for 7-weeks before use in pharmacokinetic (PK) studies and randomized by body weight (n=3-4/time point, 19-weeks of age; 28 grams). Animals were provided with water and chow ad libitum and maintained on a 12 hour light/dark cycle. Anti-DKK1 antibody RH2-18 dose solutions were prepared in a buffer consisting of 100 mM histidine, 100 mM arginine, and 6% sucrose (pH 6.0). Vehicle or RH2-18 at a dose of 2 mg/kg or 15 mg/kg was administered subcutaneously (s.c.) in a dose volume of 0.1 mL. Individual mice were sacrificed at each time point (n=3-4) and terminal blood samples were collected by cardiac puncture prior to dosing and on days 1, 4, 7, 11, 15 and 22 following dosing. Center (New Iberia, LA) weighing 4.7-12.0 kg were used. RH2-18 dose solutions were prepared in the same buffer as described above and the antibody was administered at a dose of 0.5 mg/kg or 2.5 mg/kg (s.c., 0.16 mL/kg) or infused intravenously (i.v., 0.5 mg/kg). Serial blood samples were collected from the saphenous or femoral vein pre-dose and subsequently blood samples were drawn on day 2, 3, 4, 8, 15, 22, 29, 36, 43, 50, 56, 64, 71, 78 , and 85 following antibody administration. Serum was obtained after allowing blood samples to clot for 30 min in serum separator tubes, and following centrifugation of coagulated blood (3,200 x g, 10 min, 4ºC). Serum samples were stored at -70ºC and anti-DKK1 antibody RH2-18 levels determined as described in detail below.
Pharmacokinetic analyses of anti-DKK1 antibody RH2-18 in mouse and rhesus serum samples. Recombinant rhDKK1 (235 ng/well) in PBS was used to capture anti-DKK1 antibody in 96-well EIA plate (Fisher Scientific, Pittsburgh PA). Plates were washed once with wash buffer PBST (PBS, 0.05% Tween-20), and 300 μL of blocking buffer (3% BSA, PBST) was added to each well. Plates were then incubated at room temperature for 1.5 hours. After blocking, each well was washed three times with PBST, then dried, sealed and stored at 4ºC. All serum samples were diluted 1:20 with assay buffer (2% BSA, PBST containing NaN 3 ), and subsequently diluted with 5% serum assay buffer (5% control serum in assay buffer) to concentrations of 1-100 ng/mL. Fifty μl aliquots of the previously diluted samples were added to prepared rhDKK1 coated plates in duplicate, incubated at room temperature for 1 hour and then washed three times with PBST. HRP-conjugated mouse anti-human IgG (1:3000; SouthernBiotech, Birmingham, AL) was used as detection antibody. Turbo TMB (3, 3', 5 ,5' tetramethylbenzidine; Pierce, Rockford, IL) was used as substrate with absorbance read at 450 nm following addition of stop solution (1 M sulfuric acid). Data were analyzed, using a 4-parameter curve fit for data reduction, as defined by SoftMax ® Pro (Molecular Devices, All rhesus macaque were returned after completion of the studies.
Statistical Analysis. All data are expressed as a mean ± standard error (SE). Where appropriate a one-way ANOVA followed by Dunnett's post-hoc test to detect group differences were calculated using Graphpad Prism 5.0 (GraphPad Software, LaJolla, CA).
Results
Anti-DKK1 antibody (RH2-18) neutralizes DKK1 function in vitro
Fully-human anti-DKK1 antibody RH2-18 was identified from phage displayed scFv antibody libraries and selected by consecutive panning on the basis of binding to both rhesus and mouse DKK1 proteins. Analyses of RH2-18 showed high affinity for human DKK1 (K D : 249 pM) at a discrete C-terminal epitope on DKK1 (Glantschnig et al., 2010) , a domain necessary and sufficient for LRP5/6 interaction (Brott and Sokol, 2002) and thus the antibody interferes with receptor ligand interaction (Glantschnig et al., 2010) . 
DKK1 neutralization results in a bone-pharmacodynamic response in ovariectomized mice
To evaluate pharmacokinetic properties in vivo, RH2-18 antibody (2 and 15 mg/kg) was administered to female ovariectomized (OVX) C57BL/6NTac mice by single dose subcutaneous (s.c.) injection. RH2-18 concentration in serum revealed a close to linear dose exposure relationship, with C max 138.9 ± 11.4 nM and 913 ± 122 nM, respectively. In general T max was noted at 1 to 4 days following subcutaneous administration and RH2-18 half-life (t 1/ 2 ) was 12 -19 days (Fig. 1A) . In parallel, serum mouse DKK1 levels determined by a competitive assay format designed to detect DKK1 protein not bound to RH2-18 dropped from baseline levels as expected at all doses tested. The suppression of free-DKK1 relative to the vehicle control group was nearly complete at 2.8 % (2 mg/kg), or below limit of quantification (15 mg/kg) on day 4 (Fig. 1B) . Bioavailability of DKK1 increased in both groups up to 7.3% relative to vehicle treated mice on day 23 (Fig. 1B) . (Fig. 1C) . No significant effects on serum levels of the collagen-I degradation product sCTx (CrossLaps) were detected (Fig. 1D) . Importantly, ex vivo analyses of femura and lumbar vertebrae (L3-L4) on day 24 of the study showed significant increases (p<0.05 vs. vehicle control group) in femoral ( Fig. 1E ) and lumbar spine BMD (Fig.   1F ) in both RH2-18 treatment groups. These results suggest that RH2-18 exposure mechanistically limited free DKK1 levels in parallel with increases in the bone formation marker P1NP and BMD in OVX mice.
Pharmacologic suppression of DKK1 function increases bone formation and resolves low BMD in ovariectomized mice
To further evaluate the bone mass restoring potential of DKK1 inhibition in adult (age 23 weeks at study start) osteopenic mice, we studied RH2-18 effects in OVX mice with established estrogen deficiency induced osteopenia. Animals had OVX done at 12-weeks prior to study start to allow for bone loss (-6-7% LS-BMD vs, sham control) and were treated for 8-weeks with 2 mg/kg or 20 mg/kg RH2-18 per week. As a positive control, for a robust bone effect, hPTH (1-34) at a dose that is 140-fold over the equivalent weekly clinical exposure (6) resulted in expected changes in BMD and consistent effects on dynamic and static bone histomorphometry. Terminal RH2-18 serum concentrations following multiple dosing at week 8 were 113.8 ± 2.6 nM and 332.7 ± 38.9 nM, respectively. Bioavailable free DKK1 serum levels (baseline: 8.0 ± 3.4 ng/mL) were reduced on average by >90% in all RH2-18-treated groups.
Since bone formation biomarker and BMD responses in mouse are detectable after a single dose of RH2-18, we reasoned that bone efficacy might be detectable histologically after a relatively short treatment period. To test this hypothesis, we collected histological and BMD data from mouse femura within a subset of treatment groups at day 24 ( perspective, it is significant that endosteal bone formation rates were found to be increased in RH2-18 treatment group on day 24 demonstrating the rapid onset of antibody mediated bone anabolic activity in adult osteopenic mice.
At 8 weeks of treatment, RH2-18 resolved low BMD in the femora of OVX mice to sham-OVX (Intact) vehicle levels. Overall mean-BMD in the whole femur was increased by 6.0% in the 20 mg/kg/week group ( Fig. 2A) . Similarly, BMD was higher in the distal femur ( Fig.   2B ) and central femur, representing cortical bone ( Fig. 2C ) with an increase of +7.2% and +6.6%, respectively in the 20 mg/kg/wk dose group. Consistent with the initial findings after 24 days endosteal mineralizing surface/bone surface (MS/BS) in the central femur was increased significantly (p=0.05) at 8 weeks of treatment ( Table 2 ). The increased MS/BS was primarily responsible for a significant 2-fold rise in bone formation rate/bone surface (BFR/BS) at this skeletal site. Periosteal MS/BS in the central femur rose modestly in response to treatment (Table   2) , accounting for the modest increase in periosteal BFR/BS. Consequently, central femur mean bone volume (BV/TV) was 5.8% greater than in vehicle OVX control group. The increase in endosteal bone formation and the more modest effect on periosteal bone formation, were paralleled by numerical increases in cortical area as well as reductions in endosteal perimeter (Table 2) .
Importantly, lumbar spine BMD (LV1-4) at 8-weeks was partially to completely restored in RH2-18 treatment groups to levels seen in Sham-OVX (Intact) vehicle treated controls (Fig.   2D ). This profound effect on lumbar spine aBMD was further characterized using ex vivo micro CT analysis of trabecular bone (LV3) in vehicle and RH2-18 treatment groups (Table 3) .
Volumetric analysis confirmed the significant effect on BMD by RH2-18 treatment and the overall increased bone volume (up to 27%) within the trabecular compartment. RH2-18 treatment (20 mg/kg) significantly augmented trabecular thickness (p<0.001 vs. OVX-vehicle; 13.6%) and This article has not been copyedited and formatted. The final version may differ from this version. 
Physical and biological properties of the anti-DKK1 antibody (RH2-18) enable the testing of DKK1's role in non-human primates (rhesus macaque)
To address pharmacokinetic properties in non-human primates we first administered single doses of RH2-18 (0.5 or 2.5 mg/kg) via s.c. or intravenous (i.v.) routes to rhesus macaque and then drew blood samples at the indicated time points for analysis ( 
DKK1 functions as a rate-limiting suppressor of bone mineral density in aged and ovariectomized non-human primates (rhesus macaque)
We next introduced RH2-18 (10 mg/kg/2x month) into long-term ovariectomized rhesus macaques (14-20 years of age; >8-years post-OVX). Serum RH2-18 levels at day 7 and day 71
(the last time point tested) were 681 ± 160 nM and 690 ± 201 nM, respectively, indicating extremely stable exposure of the antibody over an extended time period and suggesting absence of substantial interfering anti-human antibody response. DKK1 levels were increased by treatment from baseline 0.15 ± 0.005 nM to 29.9 ± 7.7 nM (day 8) and remained essentially unchanged to the last time point tested (27.3 ± 6.6 nM; day 71). Within this time-frame P1NP a serum marker of bone formation was consistently elevated over levels in vehicle treated controls (Fig. 4A ) while C1CP showed a significant albeit transient increase ( (Fig. 5C ).
Trabecular-vBMD (TbvBMD) of the spine showed an early treatment effect at 3-month, with a significant increase from baseline of 9.3 ± 1.8 % (mean ± SE; p=0.037), consistent with the concept that treatment with anti-DKK1 antibody RH2-18 primarily affected trabecular bone BMD. TbvBMD increased further at 6 months in most animals by 2.3 ± 0.6 % to 11.5 ± 1.6% (p<0.05) above baseline and reached a plateau at 9-month (11.5%; p<0.001). TbvBMD changes from baseline (4.6 ± 1.1%) in the vehicle group at 6-month were non-significant. Individual response size in lumbar spine TbvBMD at month 6 within the RH2-18 treatment group correlated well with early individual changes in levels of the bone formation marker P1NP from baseline at day 12 of the study (Supplemental Figure 2) . In the aggregate, data presented here demonstrate significant increases in bone mass affecting whole body and regional lumbar spine BMD in adult primates. Furthermore, a trend to increased femoral neck total aBMD by DXA was observed in the RH2-18 treatment group (p=0.047 vs. Vehicle) at 9-month.
This article has not been copyedited and formatted. The final version may differ from this version. To further investigate fracture relevant sites, we extended the analyses to distal tibia and distal radius examining vBMD and trabecular micro-architecture by hr-pQCT. Integral vBMD (combined cortical/trabecular, represented by D100 in the Scanco analyses software) of the distal tibia was found to be increased by 3.7% (p<0.001) by treatment at 9-month (Fig. 5D) , with detectable increases in trabecular thickness (TbTh) of 3.1% (p<0.01), 4.6% (p<0.005) and 5.6%
(p<0.0001) at 3, 6 and 9 months, respectively (Supplemental Figure 3) . Similar efficacies were observed in the distal radius of the treatment group at 6 and 9 months treatment, since integral vBMD showed increases of 3.6% (p<0.005) and 5.4% (p<0.005), respectively (Fig 5E) , and trabecular thickness (TbTh) showed increases of 3.0% (p<0.01) and 3.3% (p<0.005), respectively ( Fig. 5F ). Thus, anti-DKK1 antibody RH2-18 treatment positively affected bone parameters at both axial and appendicular skeletal regions in aged and ovariectomized non-human primates.
Discussion
Bone anabolic treatments targeting the Wnt-signaling pathway offer novel therapeutic approaches for systemic diseases like postmenopausal or iatrogenic osteoporosis (Khoshla et al., 2008; Deal, 2009; McCarthy and Marshall, 2010) and for localized bone loss secondary to metastatic bone disease (Yaccoby et al., 2007; Gavriatopoulou et al., 2009; Fulcnitti et al., 2009 , Heath et al., 2009 ) and rheumatoid arthritis (Diarra et al., 2007) , or in fracture repair (Bajada et al., 2009) .
Though genetic models have provided overwhelming evidence for the role of DKK1 as a crucial regulator during bone growth and development (Li et al., 2006; Morvan et al., 2006) , documentation of a role for DKK1 in the maintenance of the adult skeleton and the therapeutic potential for functional modulation of DKK1 is critical. Here we provide evidence for the inhibitory function of DKK1 in systemic low bone mass condition (osteopenia) in adult bone using an experimental therapeutic antibody. Furthermore, we show that targeting the DKK1 mechanism results in bone efficacy at multiple skeletal sites in both osteopenic murine and primate models.
The anti-DKK1 antibody described in this study displays several characteristics to address above paucity of data. First, the antibody identification strategy permitted cross-reactivity for testing in murine as well as primate species. Second, the antibody exhibits no measurable interaction with the closely related DKK2/DKK4 proteins assuring data interpretation that is tightly focused on DKK1 function (Krupnik et al., 1999; Glantschnig et al., 2010) . High-bone mass (HBM) mutations of LRP5 diminish binding of DKK1 and confer resistance to the inhibitory actions of DKK1 on LRP5/6 and Wnt-signaling (Boyden et al., 2002; Fleury et al., 2010) , thus providing a rationale for the mechanism of action of RH2-18 on bone and its efficacy via modulation of DKK1 function (Glantschnig et al., 2010) . In addition DKK1 interaction with LRP4 ) and Kremen receptors may be affected by the pharmacological action of anti-DKK1 antibody, however, this was not experimentally tested.
This article has not been copyedited and formatted. The final version may differ from this version. We demonstrate here the profound systemic effects of anti-DKK1 antibody in adult osteopenic mice at multiple skeletal sites including endosteal surfaces comprised of trabecular and cortical compartments leading to partial to complete resolution of the osteopenic phenotype.
The most notable finding in this study is that when introduced de novo into estrogendeficient osteopenic adult mice RH2-18 treatment elevated BMD to a level comparable with that of sham-operated controls within eight weeks of treatment. Wnt/β-catenin signaling has previously been reported to influence both bone formation and resorption (Baron and Rawadi, 2007; Pinzone et al., 2009 ). The anti-DKK1 antibody induced osteoanabolic activity was evidenced by increased circulating P1NP in treated mice and primates and confirmed by the observation of augmented bone formation at all endosteal surfaces examined in mouse. The approximate 2-fold increase in endosteal bone formation and detectable but non-significant effect on periosteal bone formation was paralleled by a progression towards an increase in the cortical area. The cellular process underlying this effect likely involves Wnt/β-catenin and thus a DKK1 inhibitable mechanism in the differentiation of mesenchymal progenitor cells to pre-osteoblast progenitors as well as in pre-osteoblast to osteoblast transitions (Pinzone et al., 2009 ). This interpretation is consistent with the genetic DKK1 loss of function phenotype in mice which includes both an increase in osteoblast number and elevated bone formation and paralleled by improved biomechanical strength (Morvan et al., 2006) . Thus an augmenting effect on bone strength by a pharmacologic DKK1 inhibitor is inferred; however this awaits confirmation by future studies. Further validation of on-target efficacy by the experimental antibody RH2-18 could be gained using genetic models where DKK1 protein expression is strongly reduced or preferably completely absent in the adult mouse, and thus treatment effects by anti-DKK1
antibody are expected to diminish.
Evidence suggesting a role for local Wnt-pathway modulation through DKK1 in murine bone tissue has recently been provided by models of inflammatory joint disease (Diarra et al., 2007) and multiple myeloma in immune compromised mice (Yaccoby et al., 2007; Fulciniti et al., This article has not been copyedited and formatted. The final version may differ from this version. antibodies have been shown to suppress bone resorption activity in these murine disease models (Diarra et al., 2007 , Yaccoby et al., 2007 , whereas in other studies the lack of an effect on bone resorption indices has been reported (Fulciniti et al., 2009; Heath et al., 2009 ). In general RH2-18 treatments elicited no long term effects on markers of bone-resorption but a transient suppressive effect on sCTx and uNTx levels in primates, leaving open the possibility of an associated though modest bone resorptive component in the current study. Studies in primates were non-invasive, and thus limited by the lack of information on bone histology, which could afford more detailed analyses of bone resorption processes at the tissue level. Diarra et al. have established that bone resorptive processes and the local apposition of bone (osteophyte) in joints involve particular regulatory cues controlled through DKK1, while neutralization of DKK1 also protects from systemic bone loss in inflammatory mouse models (Ruiz Heiland et al., 2010) . Further studies will be needed to evaluate the potential effect of RH2-18 anti-DKK1 antibody on the local apposition or removal of bone in healthy and diseased joints during inflammation.
In addition to the loss in bone mass, deterioration in parameters of bone quality (e.g. trabecular architecture) can increase the risk of fracture in vertebral osteoporosis (McDonnell et al., 2007 ). DKK1 appears to play a rate limiting role in the adult osteopenic skeleton and during estrogen-deficiency, since RH2-18 treatment ameliorated the reductions in lumbar spine aBMD in mouse and primates and improved parameters of bone micro-architecture in the mouse vertebra.
Likewise, lumbar spine TbvBMD of adult non-human primates improved significantly with the treatment. Importantly this effect was not limited to the axial skeleton since RH2-18 treatment notably improved integral vBMD as well as trabecular thickness at the distal radius and tibia.
Together, the findings strongly support DKK1's role as a rate limiting factor in the adult skeleton. animal models of accelerated systemic bone loss unrelated to hormonal deprivation will be of interest (Ruiz Heiland et al., 2010) .
Also consistent with a translational therapeutic effect is an early treatment response of the bone formation biomarker P1NP, which correlated moderately and positively with individual lumbar spine TbvBMD responses to RH2-18 treatment in non-human primates. Thus, the combined data provide strong evidence for an inhibitory role of DKK1 in bone homeostasis in adult ovariectomized primates and a bone anabolic response to a treatment with an experimental DKK1 neutralizing antibody resulted in bone mass accrual at multiple skeletal sites.
Given the known involvement of Wnt signaling in development and in certain cancer types, all molecules modulating the Wnt signaling pathway need to be investigated for their tumorigenicity potential and toxicity to other extra-skeletal tissues in particular in the treatment of chronic disorder such as osteoporosis (Baron and Rawadi, 2007) . A wide range of DKK1 expression levels has been reported at various phases of tumorigenesis in multiple cancer phenotypes including prostate, breast, colorectal, esophageal, lung, and multiple myeloma (Pinzone et al., 2009 ). The role of DKK1 is not completely defined and may vary depending on the cellular context, and the potential risks through modulation of DKK1 function must be considered and further evaluated, although a DKK1-antibody has recently entered clinical trials for the treatment of multiple myeloma patients (Fulciniti et al., 2009 ).
In conclusion, we provide pharmacological evidence for modulation of DKK1 bioactivity resulting in partial to complete resolution of osteopenia in murine and primate models. (n=10-14/group). One-way ANOVA, Dunnetts' test vs. Vehicle-OVX control group (* p<0.05, ** p<0.01, *** p< 0.001). One-way ANOVA, Dunnetts' test vs. vehicle control group (* p<0.05, ** p<0.01, *** p<0.001).
